Wuhan General Group Recruiting in Lesotho for its Medicinal Cannabis Cultivation Facility

CAPE TOWN, SA / ACCESSWIRE / April 20, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce on the occasion of ‘420 Day’ or ‘Weed Day’ that the company, through its local subsidiary, Tsime Pharmaceuticals and Medicinal Supplies, has started recruiting its team for the rollout of a world class medicinal cannabis cultivation facility. The first employee has already been appointed, and an experienced team of master growers engaged.

Willem Jonker, Chief Operating Officer of the cannabis division of Wuhan, commented “Lesotho was recently in the news when a local company obtained EU GMP accreditation. This confirms our belief that Lesotho is the correct location for our cultivation operations. The Lesotho government recently also approved psilocybin research, opening up further possibilities for our group in that country.”

While the recruitment continues, the company is simultaneously finalizing details for Phase 1 of the property buildout and plans to share the timeline and deliverables very soon.

“Weed Day’ or ‘420′ generally has the connotation of people smoking cannabis for recreational purposes. The day was popularized by the people categorized as ‘stoners’ due to a lack of acceptability of cannabis in people’s lives given it’s illegal status. However, people are changing and so are the laws. We as societies have grown to accept cannabis a lot more and companies such as ours are propagating the use of this God-given plant for medicinal and prescription purposes in order to positively affect the health of countless people in the world. Weed Day should no longer be celebrated or recognized only by ‘stoners’, but also by everyone who believes in the science behind plant-based and natural medicine. This is a step we all must take to rebrand the image of cannabis in people’s minds and create positive awareness.” said Jeff Robinson, CEO of Wuhan General Group.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc

View source version on accesswire.com: